Send Press Release To Your Friends

PR Title:	CellPoint Plans to Complete Phase 2b Trial in Evaluating the Presence and Severity of Coronary Artery Disease
PR Summary:	CellPoint is a biopharmaceutical company focused on the development of universal molecular imaging compounds and molecular therapeutics for the diagnosis, staging, treatment and treatment monitoring of cancer, cardiovascular disease, and a range of ischemic diseases.

	Basic Information
	Your Name* Your Email* Friend's Name Friend's Email 1* 2   3   Your Message